The inflammasome in liver disease

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

The Role of Gut Microbiota in Non-alcoholic Fatty Liver Disease
Anatomy of an Inflammasome
Peter J. Barnes, FRS, FMedSci 
Hal M. Hoffman, MD, Lori Broderick, MD, PhD 
Volume 46, Issue 3, Pages (March 2007)
Volume 66, Issue 5, Pages (May 2017)
Mechanism of Action of Colchicine in the Treatment of Gout
Inflammasomes in liver diseases
Lipotoxicity in NASH Journal of Hepatology
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Barrier Epithelial Cells and the Control of Type 2 Immunity
Inna S. Afonina, Christina Müller, Seamus J. Martin, Rudi Beyaert 
Pathways of liver injury in alcoholic liver disease
Obesity, inflammation, and liver cancer
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Therapy of autoinflammatory syndromes
Gianluca Tell, Carlo Vascotto, Claudio Tiribelli  Journal of Hepatology 
Peter J. Barnes, FRS, FMedSci 
Nonalcoholic steatohepatitis
Jean-Charles Nault, Jessica Zucman-Rossi  Journal of Hepatology 
Lipotoxicity in NASH Journal of Hepatology
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
Toll-like receptors in Borrelia burgdorferi-induced inflammation
Gut microbiota and non-alcoholic fatty liver disease: new insights
Roles for Chemokines in Liver Disease
Hal M. Hoffman, MD, Lori Broderick, MD, PhD 
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
Gut–liver immunity Journal of Hepatology
Figure 1 Activation and signalling of IL-1
Pyroptosis Current Biology
Targeting the gut-liver axis in liver disease
Inflammation and portal hypertension – The undiscovered country
Hepatitis C core protein – The “core” of immune deception?
Signalling pathways in alcohol-induced liver inflammation
Benjamin L. Woolbright, Hartmut Jaeschke  Journal of Hepatology 
Targeting gut flora to prevent progression of hepatocellular carcinoma
Biomarkers of liver cell death
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Autophagy and senescence in fibrosing cholangiopathies
Pathways of liver injury in alcoholic liver disease
H. Zhao, A. Alam, Q. Chen, M. A. Eusman, A. Pal, S. Eguchi, L. Wu, D
Volume 146, Issue 7, Pages (June 2014)
Veronika Lukacs-Kornek, Detlef Schuppan  Journal of Hepatology 
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Chengcheng Jin, Jorge Henao-Mejia, Richard A. Flavell  Cell Metabolism 
Innate sensors of pathogen and stress: Linking inflammation to obesity
Cannabinoid signaling and liver therapeutics
Volume 63, Issue 2, Pages (August 2015)
An Inflammatory Perspective on Necroptosis
Senescence in chronic liver disease: Is the future in aging?
Claire Z. Larter, Geoffrey C. Farrell  Journal of Hepatology 
Inflammasomes in Intestinal Inflammation and Cancer
Death receptor-mediated apoptosis and the liver
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Roles of Caspases in Necrotic Cell Death
Volume 61, Issue 1, Pages S79-S90 (November 2014)
Therapeutic strategies in inflammasome mediated diseases of the liver
Volume 44, Issue 5, Pages (May 2006)
Macrophage heterogeneity in liver injury and fibrosis
Inflammasome Complexes: Emerging Mechanisms and Effector Functions
Figure 2 Initiators of obesity-associated inflammation in adipocytes
Autophagy in liver diseases: Time for translation?
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Christoph Becker, Alastair J. Watson, Markus F. Neurath 
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease  Michal Pawlak,
Mechanisms and Functions of Inflammasomes
Intracellular NOD-like Receptors in Host Defense and Disease
Sachin P. Gadani, James T. Walsh, John R. Lukens, Jonathan Kipnis 
Peter J. Barnes, FRS, FMedSci 
Presentation transcript:

The inflammasome in liver disease Alexander Wree, Fabio Marra  Journal of Hepatology  Volume 65, Issue 5, Pages 1055-1056 (November 2016) DOI: 10.1016/j.jhep.2016.07.002 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 A) Inflammation is a common feature of chronic liver disease. Inflammasomes are protein complexes, which sense pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and activate the inflammatory process. PAMPs are mostly derived from the gut, due to alterations in gut microbiota composition and/or increased intestinal permeability. B) DAMPs are mostly derived from damaged hepatocytes, and include ATP, uric acid, cholesterol crystals, DNA fragments, and fatty acids. The abundance of each DAMP is dependent on the type of injury inflicted on the hepatocytes. The inflammasome can be activated either directly in hepatic stellate cells, Kupffer cells and hepatocytes (e.g., by interleukin (IL)1β, tumour necrosis factor (TNF)-α and chemokine (C-C motif) ligand (CCL)2), or indirectly through cell death and increased exposure to PAMPs. This occurs in diseases such as alcoholic hepatitis, non-alcoholic hepatosteatosis (NASH), drug induced liver injury (DILI), ischemia/reperfusion injury, cirrhosis, acute hepatitis, viral hepatitis, and fibrosis. It is thought to be a two-step process in most cases. C) STEP 1. Signalling through receptors such as toll-like receptors (TLR), upregulates the expression of inflammasome components (NLRs, ASC, pro-caspase-1 and pro- IL-1β). NLRP3 can sense a range of PAMPs and DAMPs either directly or via receptors, such as TLR. NLRP3 activation is modulated by NF-κB. STEP 2. Upon the sensing of DAMPs and PAMPs (e.g., ATP, K+ etc.), a complex encompassing NLRP3, ASC, pro-casp1 is formed. This leads to pro-caspase-1 activation and the release of mature IL-1β. Signalling is then amplified through IL-1β interacting with its receptor. Inflammasome activation and IL-1β production are associated with liver fibrosis. Journal of Hepatology 2016 65, 1055-1056DOI: (10.1016/j.jhep.2016.07.002) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions